Trial Profile
A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 09 Mar 2012 Actual initiation date changed from Sep 2007 to Dec 2007 as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual initiation date changed from Sep 2007 to Dec 2007 as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual patients number is 3 as reported by ClinicalTrials.gov.